Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Cubist Pharmaceuticals (UNKNOWN: CBST.DL ) , a biopharmaceutical company focused on developing acute-care therapies, advanced by as much as 11% after announcing positive late-stage data for its complicated urinary-tract-infection antibiotic, ceftolozane/tazobactam, also known as CXA-201.
So what: According to Cubist's press release, the antibiotic CXA-201 met the trials' primary endpoint of noninferiority to levofloxacin, which entailed a "microbiological eradication and clinical cure rate five to nine days after the end of therapy." Cubist also notes that while the trial wasn't designed to test the superiority of its antibiotic, a secondary analysis would suggest the potential for superiority over levofloxacin.
Now what: Now shareholders wait patiently for the phase 3 data on how this antibiotic performs in complicated intra-abdominal infections, which could be a much bigger market. It could also have applications in an even broader sense with treating hospital-acquired/ventilator-associated bacterial pneumonia, which it's also aiming to treat with experimental compound tedizolid phosphate. It's certainly an exciting time to be a Cubist shareholder and it's quite possible that a number of new compounds from its pipeline could be approved if things keep going its way. I would certainly suggest keeping Cubist on your watchlist moving forward.
The growth opportunity you won't want to miss
Cubist is definitely giving shareholders a lot of hope for future revenue growth-but so is this incredible tech stock which is growing twice as fast as Google and Facebook, and more than three times as fast as Amazon.com and Apple. Watch our jaw-dropping investor alert video today to find out why The Motley Fool's chief technology officer is putting $117,238 of his own money on the table, and why he's so confident this company will be a huge winner in 2013 and beyond. Just click here to watch!